Education
About Us
Working with TipRanks
Follow Us
Day One Biopharmaceuticals (DAWN)
NASDAQ:DAWN
Earnings Data
Report Date
Aug 12, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.35Last Year’s EPS
-0.05Same Quarter Last Year
Strong Buy
Based on 10 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 06, 2025
|% Change Since: -9.87%
|Next Earnings Date:Aug 12, 2025
Earnings Call Sentiment|Positive
The earnings call showcased strong revenue growth for OJEMDA, a robust financial position, and progress in clinical trials and regulatory processes, despite some seasonal challenges and high operating expenses.Company Guidance
During the first quarter of the fiscal year 2025, Day One reported strong financial performance and continued growth in the use of its product, OJEMDA, which is being positioned as the standard of care in second-line plus pediatric low-grade glioma (pLGG). OJEMDA's quarterly prescriptions increased by 16% from the previous quarter, driving net product revenue to $30.5 million. The company observed a consistent growth trajectory, with over 2,500 total prescriptions since launch. The commercial strategy focuses on expanding physician adoption and increasing the depth of prescribing among current users. Day One maintains a solid financial foundation, with operating expenses at $68.9 million and a cash balance of $473 million, allowing them to invest strategically without the need for additional financing. The company also advances its clinical pipeline, including the FIREFLY-2 trial and the DAY301 program, aiming to expand its portfolio and sustain long-term growth.OJEMDA Revenue Growth
OJEMDA achieved $30.5 million in net product revenue in Q1 2025, driven by a 16% increase in prescriptions over the prior quarter and an 11% growth in US net product revenue quarter-over-quarter.
Strong Financial Position
The company reported a cash balance of $473 million with no debt, indicating a solid financial foundation for future growth.
FIREFLY-2 Trial Progress
Enrollment for the global FIREFLY-2 confirmatory trial is progressing well, with expectations to be fully enrolled in the first half of 2026.
EMA Review for Tovorafenib
The EMA accepted Ipsen's application for tovorafenib, advancing its potential availability in the European market.
---
DAWN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
DAWN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| May 06, 2025 | $6.99 | $6.30 | -9.87% |
| Feb 25, 2025 | $11.82 | $9.87 | -16.50% |
| Oct 30, 2024 | $14.47 | $14.72 | +1.73% |
| Jul 30, 2024 | $15.36 | $15.19 | -1.11% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Day One Biopharmaceuticals (DAWN) report earnings?
Day One Biopharmaceuticals (DAWN) is schdueled to report earning on Aug 12, 2025, TBA Not Confirmed.
What is Day One Biopharmaceuticals (DAWN) earnings time?
Day One Biopharmaceuticals (DAWN) earnings time is at Aug 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is DAWN EPS forecast?
DAWN EPS forecast for the fiscal quarter 2025 (Q2) is -0.35.
---